Sepsis Clinical Trial
Official title:
Application of a Severe Sepsis Electronic Health Record Integrated Screening Tool and Management Bundle Study to Improve Sepsis Related Outcomes
Thousands of children die from Sepsis following routine infections. Many of these deaths can be prevented with earlier recognition and focused management. No tools are currently available to recognize the signs of early sepsis in children. The investigators have developed a electronic health record-based tool that will recognize children with sepsis early and trigger an alert to their hospital caregivers. The caregivers will be prompted to launch a focused management bundle that can stabilize these children, prevent further deterioration and reduce their chances of sepsis related complications and death. The proposed study will test the validity and effectiveness of this electronic tool in reducing sepsis mortality rates.
Project: Application of a Severe Sepsis Electronic Health Record Integrated Screening Tool
and Management Bundle (eASSIST-M) Study
Study Type: Prospective Cohort Outcomes Study
Background: Early recognition of severe sepsis is critical for the institution of goal-
directed therapy and for improving patient outcomes. Barriers to early recognition include
the lack of standardized tools to identify children with severe sepsis. The investigators
will study the potential impact of applying a novel Pediatric Severe Sepsis Screening Tool
(PSSST) integrated with the Electronic Health Record (EHR) to facilitate earlier detection
and effective management of severe sepsis.
Population: Patients between the ages 1 month and 18 years admitted to the hospital or
presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory
Response Syndrome (SIRS).
Primary Hypothesis: Prospective application of a PSSST electronically integrated with the
EHR can accurately diagnose pediatric patients with early signs of severe sepsis.
Primary Outcome Measure: Proportion of correctly diagnosed patients with severe sepsis among
those presenting with SIRS will be assessed to prospectively validate the sensitivity,
specificity, positive and negative predictive values of the PSSST tool.
Secondary Hypothesis 1: Application of the PSSST will reduce lag-time for the administration
of a goal-directed sepsis therapy bundle by 50%.
Outcome Measure: Time delay from diagnostic identification to critical therapeutic
intervention. Sepsis Recognition Lag Time will be defined as the time elapsed from the first
electronic alert to the first therapeutic intervention. Therapeutic interventions will be
defined as Cardiopulmonary Resuscitation (CPR), fluid resuscitation, initiation of
cardiotonic agents, or request for transfer to the ICU. Since this is an intent-to-diagnose
study, outcomes defined above will be compared with those for the same period in the
preceding year.
Secondary Hypothesis 2: Application of a severe sepsis management bundle will reduce
mortality and morbidity.
Outcome Measure: Proportion of deaths in the study population due to severe sepsis.
Morbidity will be defined as the number of ventilator days, days on vasopressor or inotropic
agents, days of Extracorporeal Membrane Oxygenation (ECMO) support, need for tracheostomy,
need for Gastrostomy tube.
Proposed Study Design:
The investigators will conduct a prospective study where patients within the ED and
inpatient units are electronically screened using the PSSST during a 3-year study period.
Patients will be screened using a novel electronic tracking tool designed locally, using
pre-defined severe sepsis variables and validated on patients with severe sepsis. Patients
screened as positive for severe sepsis using the electronic tracking tool will be treated
prospectively with a standardized severe sepsis management bundle. Data will be collected
prospectively on all patients admitted to the ED and inpatient units. For the ED and each
inpatient unit, the outcomes defined above will be compared with those for the same period
in the preceding year.
Covariates: Demographic, clinical characteristics and sepsis-specific factors that could
potentially influence the effect of the alerts on critical intervention.
Statistical Analysis:
To assess the effectiveness of this tool, we will compare the proportions of the population
with each variable of interest between the intervention and prior periods.
1. To assess the efficacy of the PSSST, we will compare the changes over time in the
proportion of patients diagnosed severe sepsis adjusting for key covariates of
interest.
2. To assess the effectiveness of the PSSST in reducing treatment delays, we will compare
changes in the Sepsis Recognition Lag Time between the intervention and control
periods, while adjusting for key covariates of interest.
3. To assess the efficacy of the PSSST in reducing mortality, we will compare the changes
in the age and risk adjusted mortality rates over time between the intervention and
control periods.
The investigators will use a robust variance estimate for all analyses to account for the
clustering of patients within units. We will also use propensity scores to control for
differences in patient characteristics and diagnostic categories.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |